Modern medicine has evolved drastically over the years. From home remedies to targeted medicines, the healthcare sector has witnessed significant breakthroughs.
Modern medicine has evolved drastically over the years. From home remedies to targeted medicines, the healthcare sector has witnessed significant breakthroughs. While some diseases are completely cured, some are still poorly understood and need significant R&D such as irritable bowel syndrome.
Irritable bowel syndrome is a gastrointestinal (GI) disorder and it affects around one-fifth of the population, especially women. Moreover, it has a direct impact on the quality of life and overall health.
In the treatment of irritable bowel syndrome, various home medicines, and modern medicines are proven to be effective. Suitable adjustments in diet and addition of some herbal remedies could go a long way. However, in severe conditions such as chronic diarrhea, abdominal pain, and constipation, the patient must visit the nearest healthcare sector or take advice from a healthcare practitioner.
The growth of the irritable bowel syndrome market is attributed to rise in prevalence of gastrointestinal diseases and disorders across the globe. Furthermore, adoption of sedentary lifestyle and launches of various developed pipeline drugs for the irritable bowel syndrome treatment are the other factors that contribute to the growth of the market.
Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/6313
Irritable bowel syndrome is a gastrointestinal tract (GT) illness with the symptoms such as alteration of bowel habits and severe abdominal pain. Usually, the digested food passes through the gastrointestinal tract (GT) and the movement of food is due to intestinal muscle contraction. The irritable bowel syndrome hinders natural movements of that muscle; thus, food material cannot pass through the digestive tract and may result in abdominal pain, diarrhea, mucus in the stool, constipation, bloating & gas, and cramping. The Centers for Disease Control and Prevention (CDC) suggested that nearly 3 million people in the U.S. were reported being treated with irritable bowel syndrome in 2015.
According to Allied Market Research, the global irritable bowel syndrome treatment market is expected to reach $2.01 billion by 2026, growing at a CAGR of 8.2% from 2019 to 2026. Increase in geriatric populations, surge in number of pipeline drugs, and rise in prevalence of gastrointestinal disorders have boosted the growth of the market.
Despite irritable bowel syndrome being the most common condition across the globe, the illness is poorly understood. However, recent years have witnessed major advancements including understanding the vital role of inflammation and altered microbiota. These medical developments have improved irritable bowel syndrome treatment significantly.
Recently, Knight Therapeutics Inc., a leading pharmaceutical company launched IBSRELA, a novel therapy for the treatment of irritable bowel syndrome with constipation in adults. IBSRELA is the minimally-absorbed minute molecule that acts in the gastrointestinal tract and helps reduce the absorption of sodium from the colon and small intestine, which results in rise in bowel movements and reduces abdominal pain. The U.S. Food and Drug Administration (FDA) has approved the medicine for patients suffering from irritable bowel syndrome in adults.
While such medicines help manage irritable bowel syndrome in adults, some additions to the diet could prove effective. Drinking a lot of water, warmth to loosen muscle, and herbs such as peppermint, carmint, turmeric, and high fiber and water-binding foods helps maintain the health of the GI tract. On the other hand, overly spicy food, caffeine, and alcohol could trigger irritable bowel syndrome and irritate the GI tract. Moreover, these foods and beverages could make digestion difficult. A proper diet and awareness about the consumption of a healthy diet could go a long way in managing irritable bowel syndrome.